Podcasts about Bayer

My co-host Ken Suzan and I are welcoming you to episode 171 of our podcast IP Fridays! Today's interview guest is the president of the German Patent and Trademark Office Eva Schewior! But before we jump into this very interesting interview, I have news for you: The US Supreme Court has taken up an important patent law case concerning so-called “skinny labels” for generic drugs. Specifically, the highest US court is reviewing a case in which Amarin accuses generic drug manufacturer Hikma of inciting doctors to use the cholesterol drug Vascepa in violation of patents by providing a limited package insert. In two landmark decisions, the UPC Court of Appeal clarified the criteria for inventive step and essentially confirmed the EPO’s typical “problem-solution” approach (Amgen v Sanofi and Meril v Edwards). However, experts are not entirely sure whether the Court of Appeal’s decisions, particularly those relating to the determination of the closest prior art, deviate from EPO practice. As a result of Brexit, mutual recognition of trademark use between the EU and the UK will cease to apply from January 1, 2026. Use of a trademark only in the UK will then no longer count as use of an EU trademark for the purpose of maintaining rights – and conversely, EU use will no longer count for British trademarks. Bayer is attacking several mRNA vaccine manufacturers in the US (Pfizer, BioNTech, Moderna, and J&J separately). The core allegation: patent infringements relating to old (Monsanto) patents on mRNA stabilization; Bayer is seeking damages, not sales bans. DISCO Pharmaceuticals from Cologne signs an exclusive license agreement with Amgen (potentially up to USD 618 million plus royalties) for novel cancer therapies targeting surface structures. Relevant from an IP perspective: license scope, milestones, data/know-how allocation. And now let's jump into the interview with Eva Schewior! The German IP System in Transition: Key Insights from DPMA President Eva Schewior In an in-depth conversation on the IP Fridays podcast, Eva Schewior, President of the German Patent and Trademark Office (DPMA), outlined how Germany's IP system is responding to rising demand, technological change, and a fundamentally altered European patent landscape. The interview offers valuable insights for innovators, companies, and IP professionals navigating patent, trademark, and design protection in Europe. Sustained Demand and Procedural Efficiency Despite the introduction of the Unitary Patent system, national German IP rights continue to see strong and growing demand. According to Schewior, application numbers at the DPMA have been increasing for years, which she views as a strong vote of confidence in the quality and reliability of German IP rights. At the same time, this success creates pressure on examination capacity. The average duration of patent proceedings at the DPMA is currently around three years and two months from filing to grant, provided applicants request examination early and avoid extensions. Internationally, this timeframe remains competitive. Nevertheless, shortening procedures remains a strategic priority. Search requests alone have risen by almost 50% over the past decade, yet the DPMA still delivers search reports on time in around 90% of cases. To better reflect applicant needs, the DPMA distinguishes between two main user groups: applicants seeking a rapid grant, often as a basis for international filings, and applicants primarily interested in a fast, high-quality initial assessment through search or first examination. Future procedural adjustments are being considered to better serve both groups. The Role of Artificial Intelligence Artificial intelligence already plays a practical role at the DPMA, particularly in patent search, classification, and the translation of Asian patent literature. Schewior emphasized that the office is closely monitoring rapid developments in AI to assess where these tools can further improve efficiency. However, she made clear that AI will remain a supporting technology. In public administration, and especially in IP examination, final decisions must always be taken and reviewed by humans. AI is seen as a way to relieve examiners of routine tasks so they can focus on substantive examination and quality. Maintaining and Monitoring Examination Quality Quality assurance is a central pillar of the DPMA's work. Schewior reported consistently positive feedback from users, but stressed that maintaining quality is a continuous task. The office applies systematic double checks for grants and refusals and uses internal quality management tools to randomly review searches and first office actions during ongoing proceedings. External feedback is equally important. The DPMA's User Advisory Board, which includes patent attorneys, startups, and patent information centers, plays a key role in identifying issues and suggesting improvements. Several of its recommendations have already been implemented. Trademark Filings and Bad-Faith Applications The trademark side of the DPMA has experienced particularly strong growth. In 2025, the office received around 95,000 trademark applications, an increase of approximately 18% compared to the previous year. Much of this growth came from abroad, especially from China. While new trademark types such as sound marks, multimedia marks, and holograms have so far seen only moderate uptake, word marks and figurative marks remain dominant. A growing challenge, however, is the rise in bad-faith trademark filings. The DPMA has responded by intensively training examiners to identify and handle such cases. Procedural reforms following EU trademark law modernization have also shifted competencies. Applicants can now choose whether to bring revocation and invalidity actions before the courts or directly before the DPMA. While courts may act faster, proceedings before the DPMA involve significantly lower financial risk, as each party generally bears its own costs. Accelerated Examination as a Practical Tool Despite rising filing numbers, the DPMA aims to avoid significant delays in trademark proceedings. Organizational restructuring within the trademark department is intended to balance workloads across teams. Schewior highlighted the option of accelerated trademark examination, available for a relatively modest additional fee. In practice, this can lead to registration within a matter of weeks, without affecting priority, since the filing date remains decisive. New Protection for Geographical Indications A major recent development is the extension of EU-wide protection for geographical indications to craft and industrial products. Since late 2025, the DPMA acts as the national authority for German applications in this area. The first application has already been filed, notably for a traditional German product. Under the new system, applications undergo a national examination phase at the DPMA before being forwarded to the EUIPO for final decision. Products eligible for protection must originate from a specific region and derive their quality or reputation from that origin, with at least one production step taking place there. The EU estimates that around 40 German products may qualify. Outreach, SMEs, and Education Schewior underlined the DPMA's statutory duty to inform the public about IP rights, with a particular focus on small and medium-sized enterprises. The office has significantly expanded its presence on platforms such as LinkedIn and YouTube, offering accessible and practical IP content. Studies show that fewer than 10% of European SMEs use IP rights, despite evidence that IP-owning companies generate higher revenues. To address this gap, the DPMA is expanding outreach formats, strengthening cooperation with educational institutions, and publishing new empirical studies, including a forthcoming analysis of patenting behavior among innovative German startups conducted with WIPO. Strategic Challenges Ahead Looking forward, Schewior identified several key challenges: insufficient awareness of IP protection among SMEs and startups, a tendency in some sectors to rely solely on trade secrets, and the growing problem of product and trademark piracy linked to organized crime. From an institutional perspective, the DPMA must remain attractive and competitive in a European system offering multiple routes to protection. This requires legally robust decisions, efficient procedures, qualified staff, and continuous investment in IT and training. Careers at the DPMA Finally, Schewior highlighted recruitment as a strategic priority. The DPMA recently hired around 50 new patent examiners and continues to seek experts in fields such as electrical engineering, e-mobility, IT, and aerospace, as well as IT specialists, lawyers, and staff in many other functions. She emphasized the DPMA's role as Europe's largest national patent office and a globally significant, stable, and family-friendly employer at the forefront of technological development. German and European Patents as Complementary Options In her closing remarks, Schewior addressed the post-UPC patent landscape. Rather than competing, German and European patent systems complement each other. For many SMEs, a German patent alone may be sufficient, particularly where Germany is the core market. At the same time, the possibility of holding both a European patent and a national German patent offers strategic resilience, as national protection can survive even if a European patent is revoked. Her key message was clear: the range of options has never been broader, but making informed strategic choices is more important than ever. If you would like, I can also adapt this article for a specialist legal audience, condense it for a magazine format, or rework it as a thought-leadership piece for LinkedIn or your website. Rolf Claessen: Today's interview guest is Eva Schewior. If you don't know her yet, she is the President of the German Patent and Trademark Office. Thank you very much for being here. Eva Schewior: I'm very happy that you're having me today. Thank you, Mr. Claessen. Rolf Claessen: Shortening the length of procedures has been a stated goal since you took office. What is the current situation, and which measures are in place to achieve this goal? Eva Schewior: First of all, I'm very glad that German IP rights are in high demand. Even though applicants in Europe have multiple options today to obtain protection for their innovations, we have seen increasing application numbers for years at my office, even after the introduction of the Unitary Patent system. I see this as very positive feedback for our work. It is clear, however, that the high number of applications leads to a constantly increasing workload. At the same time, we want to remain attractive for our applicants. This means we must offer not only high-quality IP rights but also reasonable durations of proceedings. Ensuring this remains a central and permanent objective of our strategy. The average duration of proceedings from filing to grant is currently about three years and two months, provided that applicants file an examination request within the first four months after application and do not request extensions of time limits. In other cases, the average duration of proceedings is admittedly longer. With these three years and two months, we do not have to shy away from international comparison. Nonetheless, we strive to get better. In the last few years, we were able to improve the number of concluded proceedings or to keep them at a high level. In some areas, we were even able to shorten durations of proceedings a bit, though not yet to the extent that we would have wished for. Our efforts are often overtaken by the increasing demand for our services. Just to give you an example, in the last ten to fifteen years, search requests increased by nearly fifty percent. Despite this, we managed to deliver search reports in ninety percent of all cases in time, so that customers have enough time left to take a decision on a subsequent application. I have to admit that we are not equally successful with the first official communication containing the first results of our examination. Here, our applicants need a bit more patience due to longer durations of proceedings. But I think I do not have to explain to your expert audience that longer processing times depend on various reasons, which are in no way solely to be found on our side as an examination office. To further reduce the length of proceedings, we need targeted measures. To identify them, we have analyzed the needs of our applicants. It has been shown that there are two main interests in patent procedures. About three quarters of our applicants have a very strong interest in obtaining a patent. They mainly expect us to make fast decisions on their applications. Here we find applicants who want to have their invention protected within Germany but often also wish for subsequent protection outside Germany. The remaining quarter consists of applicants that are solely interested in a fast and high-quality first assessment of the application by means of a search or a first official examination. We observe that these applicants use our services before they subsequently apply outside Germany. This latter group has little interest in continuing the procedure before my office here in Germany. We are currently considering how we can act in the best interest of both groups. What I can certainly say is that we will continue to address this topic. And of course, in general, it can be said that if we want to shorten the duration of proceedings, we need motivated and highly skilled patent examiners. Therefore, we are currently recruiting many young colleagues for our offices in Munich and Jena, and we want to make our procedures more efficient by using new technical options, thus taking workload from patent examiners and enabling them to concentrate on their core tasks and on speedy examination. Rolf Claessen: Thank you very much. I also feel that the German Patent and Trademark Office has become quite popular, especially with the start of the UPC. Some applicants seem to find that it is a very clever option to also file national patents in Germany. Eva Schewior: I think you're perfectly right, and I think we will come to this point later. Rolf Claessen: In 2023, you mentioned artificial intelligence as an important tool for supporting patent examiners. What has happened regarding AI since then? Eva Schewior: Of course, we are already successfully using AI at our office. For instance, in the field of patent search, we use AI-based tools that make our examiners' work easier. We also use AI quite successfully for classification and for the translation of Asian patent literature into English. In the meantime, we have seen a rapid development of AI in the market. I think it is strategically imperative to get an overview and to make realistic assessments of what AI is capable of doing to make our procedures more efficient. Therefore, we are observing the market to find out where AI can perform tasks so that we enable examiners to concentrate on their core business. There are many ideas right now in our office where artificial intelligence can help us tackle challenges, for instance demographic change, which certainly also affects our office, and maintaining our quality standards. We will strategically promote new tools in this field to cope with these challenges. But this much is also clear: humans will always stay in our focus. Especially in public administration, I consider it a fundamental principle that in the end, decisions must be taken and reviewed by humans. AI may help us reach our goals in a more efficient way, but it can never replace patent or trademark examiners. Rolf Claessen: You have made quality improvements in patent examination a priority and have already implemented a number of measures. How would you describe the current situation? Eva Schewior: I often receive positive feedback from different sides that our users are very satisfied with the quality of our examination, and I'm very glad about that. But maintaining this quality standard is a permanent task, and we must not become careless here. For years, for instance, we have established double checks for all grants and rejections. In addition, we have introduced a quality management tool that enables us, even during the examination process, to randomly check the quality of first office communications and searches. This helps us detect critical trends and take appropriate countermeasures at a very early stage. What is also very important when it comes to patent quality is to actively ask our customers for their feedback. We do this in different ways. Just to give you an example, we have a User Advisory Board, which is a panel of external experts implemented a couple of years ago. Discussing questions of quality is regularly on the agenda of this board. We carefully listen to criticism, ideas, and suggestions, and we have already implemented some of them for the benefit of the office and our users. Rolf Claessen: The German Patent and Trademark Office, as the largest patent and trademark office in Europe, records very high numbers of trademark applications. What are you currently especially concerned with in the trademark area? Eva Schewior: In 2025, we saw around ninety-five thousand trademark applications. This is an increase of eighteen percent compared to the previous year, and I have to say that this took us by surprise. Especially applications from outside Germany, and above all from China, have risen significantly. It is of course challenging to cope with such a sudden increase on an organizational level. Another challenge is dealing with trademark applications filed in bad faith, which we are currently seeing more and more of. We have thoroughly trained our trademark examiners on how to identify and handle such applications. As regards the new types of trademarks, the rush has been moderate so far. Sound marks, multimedia marks, or holograms are apparently not yet common solutions for the majority of applicants. The key focus remains on word marks and combined word and figurative marks. Nevertheless, I believe that the new trademark types are a meaningful supplement and may play a greater role as digitization advances. The most significant changes, however, concern procedures. Applicants can now choose whether to file revocation or invalidity actions with the courts or with our office. While courts may proceed somewhat faster, the financial risk is higher. Before the DPMA, each party generally bears its own costs, apart from exceptional cases. Rolf Claessen: How does this dynamic filing development impact the duration of trademark proceedings? Eva Schewior: This is indeed a major organizational challenge. For a long time, our trademark department managed to keep durations of proceedings very short, especially with regard to registration. Despite the recent increases in applications, especially in 2025, we hope to avoid a significant extension of processing times. We have restructured the organization of the trademark department to distribute applications more equally among teams. Applicants should also be aware that it is possible to request accelerated examination for a relatively moderate fee of two hundred euros. This often leads to registration within a very short time. The filing date, of course, always determines priority. Rolf Claessen: Since December 2025, the EU grants protection not only for agricultural products but also for craft and industrial products through geographical indications. Has your office already received applications? Eva Schewior: Yes, we have received our first application, and interestingly it concerns garden gnomes. Protected geographical indications are an important topic because they help maintain traditional know-how in regions and secure local jobs. The DPMA is the competent authority for Germany. Applications go through a national examination phase at our office before being forwarded to the EUIPO, which takes the final decision on EU-wide registration. Eligible products must originate from a specific region and derive their quality, reputation, or characteristics from that origin, with at least one production step taking place there. Rolf Claessen: The DPMA has expanded its outreach activities, including social media. What else is planned? Eva Schewior: Raising awareness of IP rights, especially among small and medium-sized enterprises, is part of our statutory duty. We currently use LinkedIn and YouTube to communicate IP topics in an understandable and engaging way. We also plan dedicated LinkedIn channels, for example for SMEs. Studies show that fewer than ten percent of European SMEs use IP rights, even though those that do earn significantly more on average. In 2026, we will further expand outreach activities, cooperate more closely with universities and educational institutions, and publish new studies, including one on the patenting behavior of innovative German start-ups conducted together with WIPO. Rolf Claessen: Where do you see the biggest future challenges in IP? Eva Schewior: Germany depends on innovation, but awareness of IP protection is still insufficient, particularly among SMEs and start-ups. Some companies deliberately avoid IP rights and rely on trade secrets, which I consider risky. Another growing concern is the increase in product and trademark piracy, often linked to organized crime. For our office, remaining attractive and competitive is crucial. Applicants have many options in Europe, so we need fast procedures, legally robust decisions, qualified staff, and modern IT systems. Rolf Claessen: The DPMA is currently recruiting. Which areas are you focusing on? Eva Schewior: Our focus is on patent examination and IT. We recently hired fifty new patent examiners and are particularly looking for experts in fields such as electrical engineering, e-mobility, IT, and aerospace. We are Europe's largest national patent office and offer meaningful, secure jobs with fair compensation and strong development opportunities. Rolf Claessen: Is there a final message you would like to share with our listeners? Eva Schewior: The Unitary Patent system has created many new options. German and European patent systems do not compete; they complement each other. For many SMEs, a German patent may already be sufficient, especially where Germany is the core market. Holding both European and national patents can also be a strategic advantage. My key message is: be aware of the options, stay informed, and choose your IP strategy deliberately. Rolf Claessen: Thank you very much for being on IP Fridays. Eva Schewior: Thank you for having me. It was a pleasure.

Am letzten Spieltag der Champions League gibt es einen durchwachsenen Abend für die deutschen Teams. Während Bayern und Bayer ihre Spiele gewinnen, gibt es für Dortmund und Frankfurt Heimpleiten. Der Kracher des Abends stieg aber in Lissabon, wo Mourinho in letzter Sekunde gegen Ex-Klub Real durch einen Torwart-Treffer die Playoffs klarmacht.

Fr Pat Driscoll on making our lives too full for God, Andrea Picotti Bayer examines upcoming Supreme Court cases in 2026, and Dr Robert Royal covers Pope Leo's new notes.

Sermon delivered on the Third Sunday After Epiphany, 2025, at Most Holy Trinity Seminary, by Rev. Tobias Bayer. Epistle: Rom. 12, 16-21. Gospel: St. Matthew 8, 1-13.

In this inaugural roundtable discussion, I dive headfirst into one of the most contentious topics at the intersection of faith and science: psychedelics and Christianity. As a relatively new Christian myself, I've been wrestling with what believers should think about these powerful substances—especially after interviewing guests whose lives were transformed by psychedelic experiences, including detransitioners who credit these substances with helping them see through lies they'd built their lives upon.I've gathered four fascinating voices for this conversation, each bringing unique expertise and perspectives. Louie Locke, a pastor of 26 years from Reno, Nevada, rates himself a one out of ten—firmly opposed to psychedelic use from a Christian perspective. He explains his concerns about entering the "second heaven" or spirit realm through means other than Jesus, warning of spiritual doors that may be opened through such substances.Cameron English, a science journalist and director of biosciences at the American Council on Science and Health, brings skepticism from both scientific and theological angles, noting the poor quality of research and drawing parallels to problematic harm reduction movements.Daniel Elliot, an Air Force veteran and counselor who has conducted research on psilocybin and spiritual wellbeing, offers a cautious middle ground as a five, distinguishing between natural substances like psilocybin and synthetic ones like MDMA.Dr. Liza Lockwood, an emergency medicine physician and medical toxicologist, presents the highest rating at seven, explaining her interest in the therapeutic potential for treating refractory depression while sharing the fascinating history of ergot poisoning from the Salem Witch Trials to the discovery of LSD.Together we explore the Greek concept of pharmakeia, whether psychedelics might be connected to the tree of knowledge of good and evil, what harm reduction really means in practice, and whether Christians should be involved in psychedelic-assisted therapy settings. This is just the first in a series exploring these questions—questions that don't have easy answers but deserve thoughtful Christian engagement.Books mentioned:-Imagine Heaven and Imagine The God of Heaven by John Burke-The Great Divorce by C.S. Lewis---WHERE TO FIND THE GUESTSLouie D Locke is the Lead Pastor of Hillside Church in Reno, Nevada, where he has served for 26 years, and also oversees eight churches across Northern Nevada and Eastern California as an Area Pastor. Married to Joni for 36 years with three adult children and eight grandchildren, Louie's life mission is to help people understand and follow God's plan, guiding them toward spiritual wholeness and mature discipleship grounded in biblical integrity. A lifelong learner with passion for history, theology, and thoughtful discussion, he enjoys exploring complex biblical topics and applying Christian principles to everyday life.- X/Twitter: @scoeyd- Church website: hillside4.orgCameron English is a writer, editor and co-host of the Science Facts and Fallacies Podcast. Before joining ACSH, he was managing editor at the Genetic Literacy Project, a nonprofit committed to aiding the public, media, and policymakers by promoting science literacy.- X/Twitter: @CamJEnglish- Website: acsh.org (American Council on Science and Health)- Podcast: Science Facts and Fallacies (with Dr. Liza Lockwood)Daniel Mark Elliott Jr., LMHCA, is a Protestant psychoanalytic counselor specializing in psychosis, dissociation, and cultural fragmentation. An Air Force veteran, psychedelic researcher, and founded Mad River Counseling. He is currently writing a book titled My Psychosis while developing a framework on how minds form reality, coherence, and meaning in fragmented societies.- X/Twitter: @Olaf_The_Third- Website: mad-river.orgDr. S. Eliza Lockwood is an emergency medicine physician and medical toxicologist who completed her fellowship at NYU in 2006 and went on to establish an ACGME-accredited program at Washington University in St. Louis. Driven by a passion for sustainable global health solutions, she has organized humanitarian relief efforts, founded a global health scholar track, and now serves as Medical Affairs Lead for Bayer, focusing on innovative approaches to malnutrition and disease prevention in developing countries. She lectures nationally and internationally on medical toxicology, tropical medicine, and global health.- X/Twitter: @DrLizaMD- LinkedIn: Liza Lockwood- Podcast: Science Facts and Fallacies (with Cameron English)- Weekly X Space: Thursdays 4-6 PM Central (with Cam and John Entine) discussing science and faith topics[00:00:00] Start[00:00:47] Introduction to Psychedelics and Christianity Roundtable[00:02:30] Rating Scale Explained: One to Ten[00:03:25] Louie Locke Introduction: Pastor, Rating One[00:05:23] Cameron English Introduction: Science Journalist, Rating Two[00:07:13] Daniel Elliot Introduction: Veteran and Counselor, Rating Five[00:08:14] Dr. Liza Lockwood Introduction: Toxicologist, Rating Seven[00:09:16] Why This Topic Matters to Stephanie[00:11:30] Louie Explains His Opposition to Psychedelics[00:19:22] Defining Pharmakeia and Biblical Sorcery[00:25:26] Cam's Journey Through Depression to Faith[00:38:17] Daniel on Natural vs Synthetic Substances[00:55:50] Dr. Liza's Scientific Perspective as a Seven[00:57:22] Salem Witch Trials to LSD: A History[01:10:32] Mid-Episode Break[01:19:45] Defining Harm Reduction and Its Failures[01:35:01] Psychedelics and the Tree of Knowledge[01:47:30] Brian Johnson's Psilocybin and Transhumanism[02:01:06] Seeking God in Mistaken Ways[02:05:20] Final Thoughts from the Panel[02:12:45] Where to Find the GuestsROGD REPAIR Course + Community gives concerned parents instant access to over 120 lessons providing the psychological insights and communication tools you need to get through to your kid. Now featuring 24/7 personalized AI support implementing the tools with RepairBot! Use code SOMETHERAPIST2025 to take 50% off your first month.PODCOURSES: use code SOMETHERAPIST at LisaMustard.com/PodCoursesTALK TO ME: book a meeting.PRODUCTION: Looking for your own podcast producer? Visit PodsByNick.com and mention my podcast for 20% off your initial services.SUPPORT THE SHOW: subscribe, like, comment, & share or donate.Watch NO WAY BACK: The Reality of Gender-Affirming Care. Use code SOMETHERAPIST to take 20% off your order.MUSIC: Thanks to Joey Pe...

Sermon delivered on the Feast of the Holy Name of Jesus, 2026, in Harrisburg, Pennsylvania, by Rev. Tobias Bayer. Epistle: Gal. 4, 1-7. Gospel: St. Luke 2, 33-40.

Sermon delivered on the Second Sunday After Epiphany, 2026, in Houston, Texas. Epistle: Rom. 12, 6-16. Gospel: St. John 2, 1-11.

Der SC Freiburg und der VfB Stuttgart gewinnen ihre Sonntagsspiele in der Bundesliga. Der BVB muss unfreiwillig einen Abwehrspieler abgeben und Leverkusen holt einen neuen Torwart!

This week Kyle, Dan, and Bear work through a series of market conversations that connect policy changes, commodities, and corporate risk.The discussion starts with recent "changes" to the food pyramid and what those shifts could mean for nutrition guidelines, consumer behavior, and the cattle industry. From there, the conversation moves into commodities more broadly, including silver and gold pushing to all-time highs and what that signals about inflation, currency confidence, and risk appetite.The group also breaks down the latest developments in Bayer's Supreme Court case, talking through the legal stakes, precedent, and how a favorable or unfavorable ruling could impact the company.Chapters & Timestamps:00:00 – Intro and opening discussion03:50 – Changes to the food pyramid09:20 – Implications for cattle and agriculture15:10 – Silver and gold at all time highs21:40 – What commodity strength is signaling27:30 – Bayer Supreme Court case overview34:15 – Likelihood and impact of a favorable ruling41:20 – Broader market takeaways47:30 – Closing thoughtsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

This episode is part of the "Inches Are All Around Us" series looking for all the little pockets—inches, if you will—that comprise the greater than $1 trillion in healthcare waste in this country annually. For a full transcript of this episode, click here. If you enjoy this podcast, be sure to subscribe to the free weekly newsletter to be a member of the Relentless Tribe. Many of these inches, if we hack them out, will actually improve patient care because these inches are just like the friction that's in the middle. To this end, I started thinking about FQHCs (Federally Qualified Health Centers), which are (these FQHCs in this context, if you think about it) kind of a great laboratory for scrappy and amazing case studies about finding and cutting out waste with some serious fiscal discipline. The thing with FQHCs and why they are great places to I spy inches of waste is really because if an FQHC has a budget shortfall, they cannot solve it by cost shifting to commercial patients, commercial members, commercial plans. They have no commercial patients.  Also, they have a patient population that many would consider challenging, and they cannot restrict access. They gotta make do with what they have. They must have actually true fiscal discipline. They either figure out how to be efficient, or their patient population does not get care. But what tipped me over the edge to revisit this episode from 2021 with Gary Campbell—who is the CEO of an FQHC, by the way—I picked the show to revisit because of my conversation with Nikki King, DHA, that I had earlier this year (EP470). Nikki and I caught up, and she is now the CEO of an FQHC in Indiana. I had interviewed Nikki, by the way, about rural health a few years ago (EP338). So, go back and listen to that if anything I say today you find intriguing for other reasons. Tribe, this is interesting to think about what I'm about to tell you. Really. I've been thinking about it for six months. I wanna start out here recapping my aforementioned catch-up conversation with Nikki King as the lead-in to my conversation with Gary Campbell to follow. And to be specific here, Gary Campbell is the CEO of an FQHC in Virginia called Johnson Health Center; and Nikki King is CEO at Alliance Health Centers in Indiana. Let me tell you one thing that Nikki King did. There are many things that she did, but here's one that she told me about. Nikki realized after talking and listening to their patients that one of the biggest barriers to getting care at her FQHC for patients was no transportation. Also, as most FQHCs, they were short on funds. So, doing things like free Ubers or something like that was not an option. So, you know what Nikki did? She thought about where her patients are. For example, most referrals to their addiction treatment services came from the courthouse—a judge remanding, if that's the right word, someone to treatment. So, two birds with one stone style, Nikki marched over to the courthouse facilities person and asked if they had any open office space at the courthouse, you know, work from home and all of that. Maybe there were some open offices. Well, the courthouse did. They had some open offices. So, now rent-free or almost rent-free, I don't, I'm not sure, when a judge says to somebody, "Go get addiction treatment," that judge can also point down the hall and the patient can just walk over. Nikki did the same thing, setting up a clinic in a day care center. She set up a clinic in a homeless shelter and right by a big basketball court. You compare and contrast this, I don't know, "just get it done" approach to all of the times that you hear about "some cash-strapped entity" who decides the best thing to do immediately is new construction. Pay to build brick and mortar and then in perpetuity, of course, pay all the costs and the snow removal and the security and the utilities and repair for that new construction. And they could be an FQHC building new buildings—one of the less scrappy ones—but it also could be a big, consolidated health system or anybody in between. It's amazing how many times you hear "razor-thin margins," and then you hear "new construction" in the same sentence. I'm like, "Yeah … gotcha. Upsize." Call it my Pennsylvania Dutch and Bronx heritage. But yeah … head exploding. That was a tangent. Bottom line, however, I say all this to say FQHCs (the ones with great leadership, at least) are a wonderful case study to look for insights on how to operate in an environment that cannot rely on, again, raising commercial rates and cost shifting to balance the budget, right? Let's not forget, there are two very different ways to end up with no profit: One is genuine struggle. The other is simply being very good at spending every dollar that is given to you. For plan sponsors, this is a vital distinction, regardless of how loud anybody cries poor, any clinical partner who lacks fiscal discipline isn't struggling; they're inefficient. And we do not have a market in healthcare to be able to tell who's struggling versus who is inefficient. So, yeah … keep that in mind and listen to episode 490 and 492 after this one with Shane Cerone and Sam Flanders, MD, for more on the whole "there's no market" theme, as well as more on the fiscal discipline topic. But again, this is why FQHCs are such a good case study here, because there's an upper limit to how much money they have. In most circumstances—I mean, barring some big donation or something like that—but under most circumstances, they have a revenue cap that they have to be disciplined enough to work within. Okay … one last thing before we kick into the show today. I wanna be really clear here. Fiscal discipline isn't something that any individual doctor or nurse or other clinician can tackle in a vacuum. Or even any given administrator. It is a leadership imperative. Great leadership doesn't just manage the clinical side. It takes accountability for the administrative waste that keeps margins thin and prices high. So, here's actionable advice for anybody listening, regardless of what you may or may not have to do with FQHCs. If you're a plan sponsor looking for a clinical partner, consider, like, what Nikki King is doing and the thinking that Gary Campbell is gonna talk about as a benchmark. Real value comes from finding the organizations that treat fiscal discipline as kind of a mission critical strategy, because these days, with all the affordability issues, it is financial toxicity is clinical toxicity. I mean, maybe you can find an organization that actually does unit cost accounting. Listen to the show with Mick Connors, MD (EP495). Okay … as I said earlier, my guest today is Gary Campbell, who I spoke with in 2021—so this is a deep cut from the archives, but it's also a really great show. Gary, as I said earlier, is CEO of Johnson Health Center, which is an FQHC, in Lynchburg, Virginia. He's also the president of Impact2Lead. Also mentioned in this episode are Impact2Lead; Johnson Health Center; Nikki King, DHA; Alliance Health Centers; Shane Cerone; Sam Flanders, MD; Kada Health; Mick Connors, MD; Aventria Health Group; John Lee, MD; Beau Raymond, MD; Amy Scanlan, MD; Eric Gallagher; Eve Cunningham, MD, MBA; Joyce Gioia; Robert Pearl, MD; Peter Attia, MD; Jerry Durham; and Tom Nash. For a list of healthcare industry acronyms and terms that may be unfamiliar to you, click here.   You can learn more at impact2lead.com and follow Gary on LinkedIn.   Gary Campbell is the founder and owner of Impact2Lead, LLC, and the president and CEO of Johnson Health Center (JHC), where he has enjoyed a career centered on leading for/not-for-profit organizations and helping to unleash potential in others along the way. In 2011, he left Bayer and went to JHC; and in 2013, he launched Impact2Lead to provide transformation-consulting services to other firms across the United States. Since joining JHC, the center has enjoyed unprecedented success and growth by transforming the culture using his Impact Leadership model and becoming the first Federally Qualified Health Center to be recognized as an Employer of Choice by Employer of Choice International, Inc. The health center has achieved multiple workplace and community awards since that time and has enjoyed exponential growth during his years as the CEO. Gary currently speaks and consults nationally on leadership, workplace strategies, and motivational topics.   09:03 Why is there no opportunity to cost shift in an FQHC? 09:34 What happens when an FQHC is operating inefficiently? 10:00 "Have you workflowed it out? … You can overstaff yourself in a way that your cost per patient goes way up." 10:23 Why is taking a lean approach not an excuse to cut staff? 11:27 EP490 and EP492 with Shane Cerone and Sam Flanders, MD. 11:35 EP438 with John Lee, MD. 11:38 EP455 with Beau Raymond, MD. 11:40 EP402 with Amy Scanlan, MD. 11:42 EP405 with Eric Gallagher. 12:48 "The nurses are linchpins to everything." 13:44 LinkedIn post from Eve Cunningham, MD, MBA. 15:10 How does standardizing care lead to personalization of care? 16:34 "Our clinical teams see that we care." 16:53 "If you don't have a vision for where you want to be two and three years down the road, you're struggling." 17:09 "I want everybody to understand, What is their why?" 19:45 Lean & Meaningful by Roger E. Herman and Joyce L. Gioia. 24:44 "You have to project plan things out that you want." 25:51 "They don't teach leadership in most medical schools."—Dr. Robert Pearl 26:46 Outlive by Peter Attia, MD. 27:55 "Get to know these clinicians." 29:39 "From a core values perspective, you can make every single decision … on core values." 30:03 "We always start with those values. … They're embedded in everything we do." 30:20 How does an FQHC or private practices that are patient-oriented attract talent? 35:24 EP297 with Jerry Durham. 35:54 "First and foremost, be visible."   You can learn more at impact2lead.com and follow Gary on LinkedIn.   Gary Campbell discusses #provider #fiscalresponsibility on our #healthcarepodcast. #healthcare #podcast #financialhealth #patientoutcomes #primarycare #digitalhealth #healthcareleadership #healthcaretransformation #healthcareinnovation   Recent past interviews: Click a guest's name for their latest RHV episode! Zack Kanter, Mark Newman, Stacey Richter (INBW45), Stacey Richter (INBW44), Marilyn Bartlett (Encore! EP450), Dr Mick Connors, Sarah Emond (EP494), Sarah Emond (Bonus Episode), Stacey Richter (INBW43)  

This episode covers: Cardiology This Week: A concise summary of recent studies What´s new in TAVI?  Digital solutions in arrhythmias Mythbusters - Gratitude is heart healthy Host: Emer Joyce Guests: JP Carpenter, Davide Capodanno, Fleur Tjong Want to watch that episode? Go to: https://esc365.escardio.org/event/2528 Want to watch that extended interview on Digital solutions in arrhythmias, go to: https://esc365.escardio.org/event/2528?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Fleur Tjong has declared to have potential conflicts of interest to report: Amsterdam UMC Innovation grant, Heath Holland TKI, Abbott, Dutch Research Council, Boston Scientific.

Host: Emer Joyce Guest: Fleur Tjong Want to watch that extended interview on https://esc365.escardio.org/event/2528?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2528 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Fleur Tjong has declared to have potential conflicts of interest to report: Amsterdam UMC Innovation grant, Heath Holland TKI, Abbott, Dutch Research Council, Boston Scientific.

Manuel Smukalla, Global Talent Impact, Skills Intelligence, and Systems Lead at Bayer, joins Workplace Stories to unpack one of the most ambitious organizational transformations underway today. As Bayer confronts significant market, legal, and profitability pressures, the company has taken a radically different approach to how work, leadership, and talent are structured, rethinking everything from management layers to career progression.In this episode, Manuel walks through Bayer's shift to Dynamic Shared Ownership (DSO), a decentralized operating model built around networks of teams, 90-day work cycles, and leaders who coach rather than control. He explains why skills visibility became a foundational requirement for this model to work and how Bayer is using skills data to democratize opportunities, improve talent flow, and fundamentally rethink careers inside a global enterprise.You'll hear how Bayer reduced management layers by more than half, redesigned leadership expectations through its VAC (Visionary, Architect, Catalyst, Coach) model, and moved toward a culture where employees are empowered, and expected, to own their work, development, and impact.You will want to hear this episode if you are interested in...[01:01] Why Bayer embarked on a radical organizational transformation.[04:30] What Dynamic Shared Ownership really means in practice.[06:55] Moving from hierarchical structures to networks of teams.[10:40] Why skills visibility became a critical business problem.[14:05] How 90-day work cycles change accountability and outcomes.[18:10] Building organizations around customer problems, not functions.[21:15] Launching skills profiles as a starting point, not an endpoint.[23:00] How Bayer's talent marketplace democratizes opportunity at scale.[27:00] The three pillars of a skills-based organization.[33:00] Rethinking careers, performance management, and feedback.[43:10] The VAC leadership model explained.[52:30] Measuring success in a decentralized organization.[53:45] Advice for organizations considering similar transformations.Dynamic Shared Ownership: Redesigning How Work Gets DoneAt the core of Bayer's transformation is Dynamic Shared Ownership, an operating model that replaces traditional hierarchies with flexible networks of teams. Manuel explains how Bayer reduced its management layers from thirteen to six and reorganized work into 90-day cycles focused on clear outcomes. After each cycle, teams reflect on what worked, what didn't, and whether the work should continue at all.This approach decentralizes decision-making and forces a shift away from command-and-control leadership. Leaders are no longer expected to direct every task; instead, they create the conditions for teams to succeed, setting direction while trusting teams to determine how outcomes are achieved.Skills as the Engine of Talent FlowFor Dynamic Shared Ownership to function, Bayer needed a new way to understand and deploy talent. Manuel shares a pivotal realization: managers were turning to LinkedIn to understand employee skills because the organization lacked internal visibility. That insight sparked Bayer's skills journey.Rather than starting with complex taxonomies, Bayer focused first on skill visibility. Employees created and maintained skills profiles, supported by workshops on how to describe capabilities effectively. Over time, this evolved into a talent marketplace that matches people to work based on skills, not job titles, career level, or location, helping democratize access to opportunities across the enterprise.Moving Talent to Work, Not Work to TalentManuel outlines three defining pillars of a skills-based organization. First, talent must move to work rather than work being constrained by static roles. Second, organizations must commit to permanent upskilling, recognizing that development is continuous, not episodic. Third, opportunities must be democratized at scale, reducing reliance on manager sponsorship or informal networks.Bayer's marketplace supports fixed roles, flex roles, and fully agile project-based work, encouraging employees to actively shape their careers while remaining accountable for outcomes. This model challenges long-held assumptions about promotions, ladders, and linear advancement.Leadership and Performance in a Decentralized WorldLeadership at Bayer has been redefined through the VAC model: Visionary, Architect, Catalyst, and Coach. Leaders set direction, help teams design how value is created, remove barriers, and support rapid cycles of learning. This requires significant unlearning for leaders shaped by traditional hierarchies.Performance management has also shifted. Goals are set in 90-day cycles at the team level, with feedback coming from peers and work leads rather than solely from a direct manager. Over time, this creates richer data on contribution and impact, but also demands a cultural shift toward transparency, shared accountability, and continuous feedback.Connect with Manuel SmukallaManuel Smukalla on LinkedInConnect With Red Thread ResearchWebsite: Red Thread ResearchOn LinkedInOn FacebookOn TwitterSubscribe to WORKPLACE STORIES

This segment opens with reflections on Howard Lutnick's remarks at the World Economic Forum, emphasizing America First policies, criticizing European dependence on China, and highlighting global energy and manufacturing concerns. The conversation transitions to Nicole Murray's market update, noting major stock losses amid tariff concerns and business news including the closure of Canyon Cafe, Bayer's Supreme Court appeal, and Missouri self-driving legislation. The hosts also discuss OpenAI's age prediction model and debate recommendations for office worker break times, weighing practicality and efficiency in modern work-life balance. #Markets #NicoleMurray #WorldEconomicForum #AmericaFirst #Stocks #BusinessNews #WorkLifeBalance #OpenAI #MarkCoxMorningShow

Hour 2 opens with coverage of President Trump's arrival in Switzerland for the World Economic Forum, highlighting Howard Lutnick's remarks on globalization and America First policies. The discussion moves to Trump's new executive order aimed at limiting large investors from buying single-family homes, protecting American homeowners, and potential changes to 401(k) usage for first-time buyers. The hour also features a market check with Nicole Murray, detailing recent losses across major indexes and business updates including Bayer's Supreme Court appeal, Missouri self-driving truck legislation, and OpenAI's age prediction model. The hour closes with lighter news, from Poison's canceled tour and Matt Damon's Netflix critique to an emu chase in Florida and studies on midlife fitness and energy slumps. #TrumpDavos #ExecutiveOrder #Housing #Markets #NicoleMurray #BusinessNews #InOtherNews #MarkCoxMorningShow

*Screwworm cases in northern Mexico are on the rise.  *The Supreme Court has agreed to hear an appeal from Bayer, the maker of Roundup herbicide.  *Nominations are open for the 2026 National Golden Spur and Ranching Heritage Association Working Cowboy awards. *We still don't have a new Farm Bill.  *Feedyard cattle in the Texas High Plains have been putting on the pounds quickly.  *Why do people buy rural Texas land?  *South Texas has been warm this winter, but that's about to change.*Lots of performance get maintenance joint injections, but is it necessary? 

KMOX legal analyst, Brad Young, joins Megan Lynch with a look at a gun rights case in Hawaii. Could a federal law regarding labeling of insecticides, allow the Supreme Court to strike judgements against Bayer and Roundup?

In today's episode of The Real Stuff, I'm sitting down with Brandon Sudduth for a vulnerable and very important conversation. Brandon is known online for creating joyful, family-centered content alongside his wife, Destene, but behind that joy is a story he carried silently for more than 35 years. For the first time publicly, Brandon opened up about experiencing sexual abuse as a child, the lifelong impact of carrying that experience in silence, and why he finally felt called to share his story — first on his own podcast (which you can watch here) and now with our audience.We talk about being raised by a single mother and how childhood sexual abuse quietly shaped Brandon's relationships, sexuality, self-worth, and emotional armor as an adult. He shares how that unspoken pain showed up in his twenties, his first marriage, and later in his relationship with Destene, including moments of fear, avoidance, and deep self-reflection. He also shares the ways in which this experience doesn't impact him on a daily basis and the interesting ways in which it weighs on him.This episode also dives into Brandon and Destene's IVF journey and how becoming a father ultimately forced Brandon to confront the parts of himself he had long avoided. We explore faith, masculinity, healing, and what it means to break generational cycles — not just for yourself, but for your children.Most powerfully, Brandon explains why he chose to finally speak out: the responsibility he feels to other survivors, especially men, and the belief that healing begins when secrets are brought into the light.Follow Brandon: https://www.instagram.com/sudduth84Follow Destene: https://www.tiktok.com/@itsdestene_Sponsors:Bayer: Check out Bayer's trusted lineup of products, available at Walmart, CVS, Amazon, and Walgreens.Laundry Sauce: Get 20% off your entire order at Laundry Sauce with code REALSTUFF at laundrysauce.com/REALSTUFFBird&Be: Visit birdandbe.com and use code REALSTUFF for 15% off your first purchase.Magnetic Me: New customers get 15% off at MagneticMe.comRitual: For a limited time, save 40% on your first month at Ritual.com/REALSTUFFVuori: Get 20% off your first order at Vuroi.com/REALSTUFFWatch this episode in video form on YouTube: https://www.youtube.com/playlist?list=PLjmevEcbh5h5FEX0pazPEtN86t7eb2OgX To apply to be a guest on the show, visit luciefink.com/apply and send us your story. I also want to extend a special thank you to East Love for the show's theme song, Rolling Stone. Follow the show on Instagram: https://www.instagram.com/therealstuffpod Find Lucie here: Instagram: https://www.instagram.com/luciebfink/ TikTok: https://www.tiktok.com/@luciebfink YouTube: https://www.youtube.com/luciebfinkWebsite: https://luciefink.com/ Subscribe to my free newsletter "The Lucie List" here: https://thelucielist.beehiiv.com/subscribeSubscribe to "The Creator Confidential": http://www.luciefink.com/confidentialExecutive Producer: Cloud10Produced by Dear Media.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Monday January 19, 2026 Bayer gets boost as US Supreme Court says it will hear Roundup case

Der BVB spielt eine erschreckend schwache erste Halbzeit in London und verliert verdient gegen Tottenham. Bayer Leverkusen hat in Piräus zwar viele Chancen, muss sich den Griechen aber trotzdem geschlagen geben und hat nun ein Euro-Endspiel!

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über den Grönland-Dämper für den Dax, Elon Musks Sandkastenstreit um RyanAir und Glyphosat-Euphorie bei Bayer. Außerdem geht es um Deutsche Bank, Ryanair, Lufthansa, Rheinmetall, Renk, Thales, Dassault Aviation, BMW, Mercedes, VW, Hermes, Kering, Adidas, Douglas, Bayer, Under Armour, Bath & Body Works, Campbell's, Kraft Heinz, CarMax, AmeriCold, Healthpeak Properties, Comcast, Mondelez und Broadridge Financial Solutions. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Bei BVB-Gegner Tottenham brennt vor dem Königsklassen-Spiel der Baum. Die Dortmunder könnten mit einem Sieg für ein Trainer-Aus in London sorgen. Bayer 04 braucht nach dem schwachen Start nach der Winterpause endlich wieder ein Erfolgserlebnis und Markus Krösche erklärt das Toppmöller-Aus bei der Eintracht.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über neue Hoffnung bei Novo Nordisk, Quanten-Angst beim Bitcoin und einen Erfolg für Bayer. Außerdem geht es um Micron, Worthington Steel, Klöckner & Co., Eli Lilly, Viking Therapeutics, Meta, Alphabet, Microsoft, Amazon, BMW, Maersk, Legrand, Nvidia, Tesla, den iShares MSCI World Energy Sector (WKN: A2PHCF), den Xtrackers MSCI World Energy (WKN: A113FF), den VanEck Uranium and Nuclear Technologies (WKN: A3D47K), den Xtrackers FTSE Vietnam Swap ETF (WKN: DBX1AG) und den VanEck Vietnam ETF (WKN: A2AHKE). Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In our news wrap Friday, President Trump ramped up his threats about taking over Greenland and suggested that he may place tariffs on countries that don't support the move, the Supreme Court says it will hear an appeal from Bayer to block thousands of state lawsuits claiming its Roundup weedkiller causes cancer and the Trump administration says it will delay involuntary student loan collections. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Following a framework plan announced by Democrat legislators yesterday, Senate Republican leaders today discussed their own framework plan to bring additional assistance for farmers and specialty crop farmers. The Supreme Court today agreed to hear Bayer's challenge to Roundup litigation. 

In our news wrap Friday, President Trump ramped up his threats about taking over Greenland and suggested that he may place tariffs on countries that don't support the move, the Supreme Court says it will hear an appeal from Bayer to block thousands of state lawsuits claiming its Roundup weedkiller causes cancer and the Trump administration says it will delay involuntary student loan collections. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

In this enlightening episode, Guy interviewed Cyndi to explore overarching themes of holistic health, empowerment, community, and personal journey through adversity and spiritual growth. The conversation delved into how modern influences are detrimentally impacting mental, physical, and spiritual well-being, and emphasizes the importance of self-education and community support. Cyndi shared her inspiring family background, the legacy of her parents, and transformative experiences that shaped her pursuit of health and wellness. The discussion also touched on her focus on local, sustainable farming practices and the impact of legislative decisions on personal and community health. Cyndi provided actionable insights on the significance of choosing real food, supporting local businesses, and fostering innate intelligence for a more empowered and healthier life. About Cyndi: Cyndi O'Meara is a nutritionist and educator whose greatest love is to teach, both in the public arena and within the large corporate food companies, and to enable everyone to make better choices so they too can enjoy greater health throughout their lives.  Her unique, surprisingly simple yet extensively researched but down-to-earth approach, challenges and encourages others to eliminate unhealthy habits and has inspired thousands to make smarter choices about the food they choose to put into their body. Cyndi confronts her audiences, whether within the public or corporate sectors, she has the courage to call out deception and misinformation and believes in arming people with the tools and resources to reach their goals. By educating people on food choices, how to read food labels, why diets don't work, and how drugs can affect your total well-being and vitality, Cyndi empowers them to make long lasting changes with simple and achievable steps on how to create healthier habits. Key Points Discussed:  (00:00) - The Great Disconnect — How We Lost Touch With Our Body, Health, & Inner Knowing! (00:33) - Meet Cyndi: A Go-Getter's Background (01:31) - Family Influence and Upbringing (02:41) - Health Journey and Philosophy (08:22) - Educational Path and Realizations (08:56) - Adventures and Further Education (13:18) - Current Practices and Beliefs (16:53) - Community and Local Support (23:37) - Facing Adversity and Family Challenges (25:28) - Family History of Hemophilia (26:32) - The Impact of Bayer's Negligence (28:06) - Personal Losses and Reflections (30:49) - Spiritual Awakening and Healing (31:58) - Advocacy and Education (41:56) - Future Plans and Legacy (46:54) - Final Thoughts and Empowerment How to Contact Cyndi O'Meara:changinghabits.com.au whatswithwheat.com   About me:My Instagram: www.instagram.com/guyhlawrence/?hl=en Guy's websites:www.guylawrence.com.au www.liveinflow.co''

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Lea Oetjen über bittere Enttäuschungen bei den US-Großbanken, die fünf Blockbuster von Bayer und den großen Oracle-Streit. Außerdem geht es um Bank of America, Citigroup, Wells Fargo, Tesla, Fresenius Medical Care, RWE, KKR & Co, Apollo Global Management, EQT AB, iShares MSCI Japan (WKN: A0DK60), Vanguard FTSE Japan Distributing (WKN: A1T8FU) und Amundi Core MSCI Japan (WKN: LYX0YC). Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Gabrielle Union stops by to chat about her upcoming projects, family, travel, and her partnership with Bayer for the ‘Life Doesn't Stop for a Hot Flash' campaign. Also, Sarah Jessica Parker drops in to discuss winning the Golden Globe ‘Carol Burnett Award,' her new documentary ‘The Librarians,' and what it's like saying goodbye to ‘And Just Like That…' Plus, TODAY lifestyle and fashion contributor Melissa Garcia and celebrity hairstylist Rita Hazan team up to give a few lucky mom listeners a makeover. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Hope Rugo and Dr. Vivek Subbiah discuss innovative trial designs to enable robust studies for smaller patient populations, as well as the promise of precision medicine, novel therapeutic approaches, and global partnerships to advance rare cancer research and improve patient outcomes. TRANSCRIPT  Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center [in Los Angeles]. The field of rare cancer research is rapidly transforming thanks to progress in clinical trials and treatment strategies, as well as improvements in precision medicine and next-generation sequencing that enable biomarker identification. According to the National Cancer Institute, rare cancers occur in fewer than 150 cases per million each year, but collectively, they represent a significant portion of all cancer diagnoses. And we struggle with the appropriate treatment for these rare cancers in clinical practice. Today, I am delighted to be joined by Dr. Vivek Subbiah, a medical oncologist and the chief of early-phase drug development at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Subbiah is the lead author of a paper in the ASCO Educational Book titled "Designing Clinical Trials for Patients with Rare Cancers: Connecting the Zebras," a great title for this topic. He will be telling us about innovative trial designs to enable robust studies for small patient populations, the promise of precision medicine, and novel therapeutic approaches to improve outcomes, and how we can leverage AI now to enroll more patients with rare cancers in clinical trials. Our full disclosures are available in the transcript of this episode.  Dr. Subbiah, it is great to have you on the podcast today. Thanks so much for being here. Dr. Vivek Subbiah: Thank you so much, Dr. Rugo, and it is an honor and pleasure being here. And thank you for doing this podcast for rare cancers. Dr. Hope Rugo: Absolutely. We are excited to talk to you. And congratulations on this fantastic paper. It is such a great resource for our community to better understand what is new in the field of rare cancer research. Of course, rare cancers are complex and multifaceted diseases. And this is a huge challenge for clinical oncologists. You know, our clinics, of course, cannot be designed as we are being very uni-cancer focused to just be for one cancer that is very rare. So, oncologists have to be a jack of all trades in this area. Your paper notes that there are approximately 200 distinct types of rare and ultra-rare cancers. And, by definition, all pediatric cancers are rare cancers. Of course, clinical trials are essential for developing new treatment strategies and improving patient outcomes, and in your paper, you highlight some unique challenges in conducting trials in this rare cancer space. Can you tell us about the challenges and how really innovative trial designs, I think a key issue, are being tailored to the specific needs of patients with rare cancer and, importantly, for these trials? Dr. Vivek Subbiah: Rare cancers present a perfect storm of challenges. First, the patient populations are very small, which makes it really hard to recruit enough participants for traditional type trials. Second, these patients are often geographically dispersed across multiple cities, across multiple states, across multiple countries, across multiple zip codes. So, logistics become complicated. Third, there is often limited awareness among clinicians, which delays referrals and diagnosis. Add to that regulatory hurdles, funding constraints, and you can see why rare cancer trials are so tough to execute. To overcome these barriers, we are seeing some really creative novel trial designs. And there are four different types of trial designs that are helping with enrolling patients with rare cancers. The first one is the basket trial. So let us talk about what basket studies are. Basket studies group patients based on shared genetic biomarkers or shared genetic mutations rather than tumor type. So instead of running separate 20 to 30 to 40 trials, you can study one therapy across multiple cancers. The second type of trial is the umbrella trial. The umbrella trials flip that concept of basket studies. They focus on one cancer type but test multiple targeted therapies within it. The third category of innovative trials are the platform studies. Platform trials are another exciting innovation. They allow new treatment arms to be added or removed as the data matures and as the data evolves, making trials more adaptive and efficient. The final category are decentralized tools in traditional trials, which are helping patients participate closer to where they are so that they can sleep in their own bed, which is, I think, a game changer for accessibility.  These designs maximize efficiency and feasibility for rare cancer research and rare cancer clinical trials. Dr. Hope Rugo: I love the idea of the platform trials that are decentralized. And I know that there is a trial being worked on with ARPA-H (Advanced Research Projects Agency for Health) funding in triple-negative breast cancer as well as in lung cancer, I think, and others with this idea of a platform trial. But it is challenged, I think, by precision medicine and next-generation sequencing where some patients do not have targetable markers, or there isn't a drug to target the marker. I think those are almost the same thing. We have really seen that these precision medicine ideas and NGS have moved the needle in helping to identify genetic alterations. This helps us to be more personalized. It actually helps with platform studies to customize trial enrollment. And we hope that this will result in better outcomes. It also allows us, I think, to study drugs even in the early stage setting more effectively. How can these advances be best applied to the future of rare cancers, as well as the challenges of not finding a marker or not having a drug? Dr. Vivek Subbiah: Thank you so much for that question. I think precision medicine and next-gen sequencing, or NGS, are truly the backbone of modern precision oncology. They have transformed how we think about cancer treatment. Instead of treating based on where the tumor originated or where the tumor started, we now look at the genetic blueprint of cancer. The NGS or next-gen sequencing allows us to sequence millions of DNA fragments quickly. Twenty, 30 years ago, they said we cannot sequence a human genome. Then it took almost a decade to sequence the first human genome. Right now, we have academic centers and commercial sequencing companies that are really democratizing NGS across all sites, not just in academic centers, across all the community sites, so that NGS is now accessible. This means that we can identify these actionable alterations like picking needles in haystacks, like NTRK fusions, RET fusions, or BRAF V600E alterations, high tumor mutational burden. This might occur across not one tumor type, across several different tumor types. So for rare cancers, this is critical because some of these mutations often define the best treatment option. Here is why this matters. Personalized therapy, right? Instead of a one-size-fits-all approach, we can tailor treatment to the patient's unique molecular profile. For trial enrollment, this can definitely help because patients can join biomarker-driven trials even if their cancer type is rare or ultra-rare. NGS technology has also helped us in designing rational studies. Many times monotherapy does not work in these cancers. So we are thinking about rational combination strategies. So NGS technology is helping us. Looking ahead, I see NGS becoming routine in clinical practice, not just at major niche academic centers, but everywhere. We will see more tumor-agnostic approvals, more molecular tumor boards guiding treatment decisions in real time. And I think we are seeing an expanded biomarker setup. Previously, we used to have only a few drugs and a handful of mutations. Now with homologous recombination defects, BRCA1/2 mutation, and expanding the HRD and also immunohistochemistry, we are expanding the biomarker portfolio. So again, I personally believe that the future is precision. What I mean by precision is delivering the right drug to the right patient at the right time. And for rare cancers, this isn't just progress. It is survival. And it is maybe the only way that they can have access to these cutting-edge precision medicines. Dr. Hope Rugo: That is so important. You mentioned an important area we will get to in a moment, the tumor-agnostic therapies. But as part of talking about that, do you think that the trials should also include just standard therapies? You know, who do you give an ADC to and when with these rare cancers? Because some of them do not have biomarkers to target and it is so disappointing for patients and providers where you are trying to screen a patient for a trial or a platform trial where you have one arm with this mutation, one arm with that, and they do not qualify because they only have a p53 loss, you know? They just do not have the marker that helps them. But we see this in breast cancer all the time. And it is tough because we don't have good information on the sequencing. So I wonder, you know, just because for some of these rare cancers it is not even clear what to use when with standard treatments. And then that kind of gets into this idea of the tumor-agnostic therapies that you mentioned. There are a lot of new treatments that are being evaluated. We have seen approval of some treatments in the last few years that are tumor-agnostic and based on a biomarker. Is that the best approach as we go forward for rare cancers? And what new treatment options are most exciting to you right now? Dr. Vivek Subbiah: Tumor-agnostic therapies, really close to my heart, are real breakthrough therapies and represent a major paradigm shift in oncology. Traditionally, for the broad listeners here, we are used to thinking about designing clinical trials and therapy like where the cancer originated, breast cancer, kidney cancer, prostate cancer, lung cancer. A tumor-agnostic therapy flips that model. Instead of focusing on the organ, they target the specific genetic alteration or biomarker that drives cancer growth regardless of where the tumor started, regardless of the location of the tumor, regardless of the zip code of the tumor. So why is this so important for rare cancers? Because many rare cancers share molecular features with more common cancers. For instance, NTRK fusion might occur in pediatric sarcoma, a salivary gland tumor, or a thyroid cancer. Historically, each of these would require separate trials, which is nearly impossible, unfeasible to conduct in these ultra-rare cancers like salivary gland cancer or pediatric sarcomas. Tumor-agnostic therapies allow us to treat all those cancers with the same targeted drug if they share that biomarker. Again, we are in 2025. The first tissue-agnostic approval, the historic precedent, was in fact an immunotherapy. Pembrolizumab was approved in 2017, May 2017, as the first immunotherapy to be approved in a tumor-agnostic way for a genomic biomarker, for MSI-High and dMMR cancers. Then came the NTRK inhibitors. So today we have not one, not two, but three different NTRK inhibitors: larotrectinib, entrectinib, and repotrectinib, which show response rates of nearly more than 60 to 75% across a handful of dozens and dozens of cancer types. Then, of course, we have RET inhibitors like selpercatinib, which is approved tissue-agnostic, and pralsetinib, which also shows tissue-agnostic activity across multiple cancers. And more recently, combination therapy with a BRAF and MEK combination, dabrafenib and trametinib, received tumor-agnostic approval for all BRAF V600E tumors with the exception of colorectal cancer. And even recently, you mentioned about antibody drug conjugates. Again, I think we live in an era of antibody drug conjugates. And Enhertu, trastuzumab deruxtecan, which was used first in breast cancer, now it is approved in a histology-agnostic manner for all HER2-positive tumors defined by immunohistochemistry 3+. So again, beyond NGS, now immunohistochemistry for HER2 is also becoming a biomarker. So again, for the broad listeners here, in addition to comprehensive NGS that may allow patients to find treatment options for these rare cancers for NTRK, RET, and BRAF, immunohistochemistry for HER2 positivity is also emerging as a biomarker given that we have a new FDA approval for this. So I would say personally that these therapies are game changers because they open doors for patients who previously had no options. Instead of waiting for years for a trial in their specific cancer type, they can access a treatment based on their molecular profile. I think it is precision medicine at its finest and best. Looking ahead, the third question you asked me is what is exciting going on? I think we will see more of these approvals. My hope is that today, I think we have nine to ten approvals. My hope is that within the next 25 to 50 years, we will have at least 50 to 100 drugs approved in this space based on a biomarker, not based on a location of the tumor type. Drug targeting rare alterations like FGFR2 fusions, FGFR amplifications, ALK fusions, and even complex signatures like high tumor mutational burden. I think we will be seeing hopefully more and more drugs approved. And as sequencing becomes routine, we will identify more patients for these therapies. I think for rare cancers, this is not just innovative approach. This is essential for them to access these novel precision medicines. Dr. Hope Rugo: Yeah, that is such a good point. I do think it is critical. Interestingly in breast cancer, it hasn't been, you know, there is always like two patients in these tumor-agnostic trials, or if that. You know, I think I have seen one NTRK fusion ever. I think that highlights the importance for rare cancers. And you know, I am hoping that that will translate into some new directions for some of our rarer and impossible-to-treat subtypes of breast cancer. It is this kind of research that is really going to make a difference. But what about those people who do not have biomarkers? What if you do not fit into that? Do you think there is a possibility of trying to do treatments for rare cancers in some prospective way that would help with that? You know, it is really a huge challenge. Dr. Vivek Subbiah: Absolutely. I think, you know, you're right, usually many of these rare cancers are driven by specific biomarkers. And again, some of the pediatric salivary gland tumors or pediatric sarcomas like fibrosarcomas, they are pathognomonic with NTRK fusions. And again, given that we have a tumor-agnostic approval, now these patients have access to these therapies. And I do not think that we would have had a trial just for pediatric fibrosarcomas with NTRK fusions. So that is one way. Another way is SWOG, right? The SWOG DART [1609] had this combination dual checkpoint, it was called the DART study dual combination chemotherapy with ipi/nivo. Now here the rare cancer subtype itself becomes a biomarker and they showed activity across multiple rare cancer subtypes. They didn't require a biomarker. As long as it was a rare or ultra-rare cancer, these patients were enrolled into the SWOG DART trial and multiple arms have read out. Angiosarcoma, Kaposi sarcoma, even gestational trophoblastic disease. Again, they have shown responses in these ultra-rare, rare cancers. Sometimes they might be seeing one or two cases a whole year. And I think this SWOG effort, this cooperative group effort, really highlighted the need for such studies without biomarkers as well. Dr. Hope Rugo: That is such a fantastic example of how to try and treat patients in a collaborative way. And in the paper, you also emphasize the need for collaborative research efforts, you know, uniting resource expertise across different ways of doing research. So cooperative groups, advocacy organizations that can really help advance rare cancer research, improve access to new therapies, and I think importantly influence policy changes. I think this already happened with the agnostic approvals. Could you tell us more about that? How can we move forward with this most effectively? Dr. Vivek Subbiah: Personally, I believe that collaboration is absolutely critical and essential for rare cancer research. No single institution, no single individual, or no single state or entity can tackle these challenges alone. The patient populations are small and dispersed. So pooling resources is the only way to run these meaningful trials. Again, it is not like singing, it is like putting a huge, huge, I would say, an opera piece together. It is not a solo, vocal therapy, but rather putting a huge opera piece like Turandot. You know, you mentioned cooperative groups. Cooperative groups, as I mentioned earlier, the SWOG DART program, the ASCO [TAPUR study]. ASCO is doing a phenomenal work of the TAPUR study. Again, this ASCO TAPUR program has enrolled so many patients with rare cancers who otherwise would not have treatment options. NCI-MATCH, the global effort, right? NCI-MATCH and the ComboMATCH are great examples. They bring together hundreds of sites, thousands of clinicians to run large-scale trials that would be impossible for any individual center or institution. These trials have already changed practice. For instance, the DART demonstrated the power of immunotherapy in rare cancers and influenced NCCN guidelines. One of the arms of the NCI-MATCH study from the BRAF V600E arm contributed towards the BRAF V600E tissue-agnostic approval. So, the BRAF V600E tissue-agnostic approval was by a pooled analysis of several studies. The ROAR study, the Rare Oncology Agnostic Research study, the NCI-MATCH dataset of tumor-agnostic cohort, and another pediatric trial, and also evidence from literature and evidence of case reports. And all this pooled analysis contributed to the tissue-agnostic approval of BRAF V600E across multiple rare cancers. There are several patient advocacy organizations which are the real unsung heroes here. Groups like, for instance, we mentioned in the paper, Target Cancer Foundation, don't just raise awareness for rare cancer research, they actively connect patients to trials providing financial, emotional support, and even run their own studies like the TRACK trial. They also influence policy to make access easier. On a global scale, initiatives like DRUP in the Netherlands, the ROME study in Italy, the PCM4EU in Europe are expanding precision medicine across these borders. These collaborations accelerate research, improve trial enrollment, and ensure patients everywhere can have access to these cutting-edge therapies. Again, it is truly a team effort, right? It is a multi-stakeholder approach. Researchers, clinicians, investigators, industry, regulators, academia, patients, patient advocates, and their caregivers all working together. And it takes a village. Dr. Hope Rugo: Absolutely. I mean, what a nice response to that. And I think really exciting and it is great to see your passion about this as well. But it helps all of us, I think, getting discouraged in treating these cancers to understand what is happening moving forward. And I think it is also a fabulous opportunity for our junior colleagues as they rise up in academics to be involved in these international collaborative efforts which are further expanding. One of the things that comes up for clinical trials for patients, and I think it is highlighted with rare cancers because, as you mentioned, people are all over the place, you know, they are so rare. They are all far away. Our patients are always saying to us, "Should I go here for a phase 1 trial?" Can you talk a little bit about how we can overcome these financial and geographic burdens for the patients? You talked about having trials locally, but it is a big financial and just social burden for patients. Dr. Vivek Subbiah: Great point. Financial cost is a major barrier in rare cancer clinical trials. It is a major barrier not just in rare cancer clinical trials, but in clinical trials in general. The economics of rare cancer research are one of the toughest challenges we face. Developing a new drug is already expensive, often billions of dollars. On an average, it takes 2 billion dollars or 2.8 billion dollars according to some data from drug discovery to approval. For rare cancers, the market is tiny, which means the pharmaceutical companies have really little financial incentive to invest. That is why initiatives like the Orphan Drug Act were created to provide tax credits, grants, and market exclusivity to encourage development for rare diseases. Clinical trials themselves are expensive because the small patient populations mean longer recruitment times and higher per-patient costs. Geographic dispersion, as you mentioned, for the patients adds travel, coordination. That is why we need to think out of the box about decentralized trial infrastructure so that we can mitigate some of these expenses. Complex trial designs like basket or platform trials sometimes require sophisticated data systems and regulatory oversight. That is a challenge. And I think some of the pragmatic studies like ASCO TAPUR have overcome those challenges. Advanced technologies like next-gen sequencing and molecular profiling also add significant upfront cost to this. Funding is also limited because rare cancers receive less attention compared to common cancers. Public funding and cooperative group trials help a lot, but I think they cannot cover everything. Patient advocacy organizations sometimes step in to bridge these gaps, but sustainable financing remains a huge challenge. So, the bottom line is without financial incentives and collaborating funding models, many promising therapies for rare cancers would never make it to patients. That is why we need system-wide policy changes, global partnerships, and innovative, effective, seamless trial designs which are so critical so that they can help reduce the cost and make research feasible so that we can deliver the right drug to the right patient at the right time. Dr. Hope Rugo: There is a lot of excitement about the future integration of AI in screening. Just at the San Antonio Breast Cancer meetings, we have a number of different presentations about AI to find markers, even like HER2, and using AI where you would screen and then match patients to clinical trials. Do you have any guidance for the rare cancer community on how to leverage this technology in order to optimize patient enrollment and, I think, identification of the best treatment matches? Dr. Vivek Subbiah: I think artificial intelligence, AI, is a game-changer in the making. Right now, clinical trial is clunky. Matching patients to trial is often manual, time consuming, laborious. You need a lot of personnel to do that. AI can automate this process by analyzing genomic data, medical records, and trial eligibility criteria to find the best matches quickly, accurately, and effectively. For the community, the key is to invest in data standardization and interoperability because AI needs clean, structured data to work effectively. Dr. Hope Rugo: Thank you so much, Dr. Subbiah, for sharing these fantastic insights with us on the podcast today and for your excellent article. Dr. Vivek Subbiah: Thank you so much. Dr. Hope Rugo: We thank you, our listeners, for joining us today. You will find a link to Dr. Subbiah's Educational Book article in the transcript of this episode. And please join us again next month on By the Book for more insightful views on key issues and innovations that are shaping modern oncology.  Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Hope Rugo   @hoperugo   Dr. Vivek Subbiah @VivekSubbiah Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:       Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx   Dr. Vivek Subbiah: Consulting/Advisory Role: Loxo/Lilly, Illumina, AADI, Foundation Medicine, Relay Therapeutics, Pfizer, Roche, Bayer, Incyte, Novartis, Pheon Therapeutics, Abbvie Research Funding (Inst.): Novartis, GlaxoSmithKline, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg Pharma, Bayer, Incyte, Fujifilm, PharmaMar, D3 Oncology Solutions, Pfizer, Amgen, Abbvie, Mutlivir, Blueprint Medicines, Loxo, Vegenics, Takeda, Alfasigma, Agensys, Idera, Boston Biomedical, Inhibrx, Exelixis, Amgen, Turningpoint Therapeutics, Relay Therapeutics Other Relationship: Medscape, Clinical Care Options

In this episode, Rodrigo Santos, President of the Crop Science Division at Bayer, joins Andy and Tom to reflect on 2025 and look ahead to 2026. Rodrigo shares how Bayer is expanding their field organization, growing the Preceon® Smart Corn System, and leveraging digital tools to accelerate innovation. He also discusses Bayer's global farming insights from South America, the evolution of sustainability practices, and what's coming for the ForGround program. From managing legal challenges to forging stronger grower relationships, this conversation covers Bayer's multi-pronged strategy for the future of agriculture.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über einen Ritterschlag für Intel, Rebound bei Rüstung und einen Branchen-Deal der Superlative. Außerdem geht es um Apple, Garmin, Thermo Fisher, Boston Scientific, Johnson Health Tech, Planet Fitness, Life Time, Gym Group, Basic Fit, Xponential Fitness, Technogym, Nike, Adidas, Puma, Lululemon, Lockheed Martin, L3Harris, Kratos Defense, Nvidia, Oracle, Apple, Palantir, Bayer, Puma, Tilray Brands, General Motors, Elevance Health, Centene, Cigna, UnitedHealth und Molina Healthcare, Rio Tinto, Glencore, BHP Group, Siemens, Meta und Keller Group. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

TODAY ON THE ROBERT SCOTT BELL SHOW: Fentanyl Vaccine Claims, Bayer Loses Immunity Fight, Silver Nanotech Breakthrough, Happiness Protects Health, Squilla Maritima, Seniors Overmedicated Crisis, Rep. Jennifer Wortz, Parental Rights, Anti-Property Radicalism, Caller of The Day, and MORE! https://robertscottbell.com/experimental-vaccine-claims-bayer-loses-immunity-fight-silver-nanotech-breakthrough-happiness-protects-health-squilla-maritima-seniors-overmedicated-crisis-rep-jennifer-wortz-parental-rights-a/https://boxcast.tv/view/fentanyl-vaccine-claims-bayer-loses-immunity-fight-silver-nanotech-breakthrough-rep-jennifer-wortz-parental-rights---the-rsb-show-1-6-26-as6ep4ttvjpqmfvdehb5 Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

Today's guest is Vaithi Bharath, Associate Director of Data Science & AI Solutions at Bayer. Bharath joins Emerj Editorial Director Matthew DeMello to break down why clinical R&D timelines often slip for reasons that have little to do with model performance. Rather, delays compound when data moves across fragmented systems, teams rely on slow handoffs, and validation requirements turn minor adjustments into major cycle-time hits. He walks through where decision-making slows from data capture through database lock, and what it takes to accelerate workflows without replacing a validated environment. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast! This episode is sponsored by AnswerRocket.

What happens when you discover your partner has over $400,000 in student loan debt and they didn't even know it existed?In today's audience caller episode of The Real Stuff, I'm sitting down with Brittany, a listener who bravely came on the podcast to share one of the most raw, honest, and financially transparent stories we've ever featured.Brittany opens up about putting herself through college after her parents divorced, graduating with $100,000 in student loan debt, and spending her 20s working nonstop to pay it off while attending a private university surrounded by students from much wealthier families. She had a clear financial plan for her life: get her master's degree, become debt-free before 30, and feel financially secure before starting a family… then she met her now-husband.One night, lying in bed scrolling on her phone, Brittany discovered something that completely changed the course of their relationship. The student loan debt her partner believed was around $200,000 was actually more than $400,000, and she was the one who had to uncover it, piece it together, and tell him the truth.In this episode, Brittany shares exactly how she found the debt, what it felt like to confront the person she loved most, and why this discovery shattered her sense of trust, security, and honesty in their relationship. We talk about why this wasn't just about money, but about transparency, reliability, and the emotional weight we attach to financial independence. She opens up about how she processed everything, the guilt and shame she felt for questioning her relationship because of money, and how unsupported she felt when others minimized her concerns.What makes this conversation especially powerful is Brittany's willingness to be incredibly specific. We talk REAL numbers — student loan balances, salaries, mortgage payments, rent, savings, and the sacrifices required to pay off hundreds of thousands of dollars in debt without letting it completely control their lives. Brittany also shares how navigating debt reshaped their relationship, became the foundation of their marriage, and ultimately forced them to redefine what success and happiness really look like. We also talk about family planning, having their first baby, choosing to leave a three-bedroom house with a low mortgage to live in a one-bedroom apartment in the NYC area, and why she's never been happier — proving that happiness and fulfillment don't always come from traditional financial milestones.If you've ever felt ashamed about debt, questioned a relationship because of money, or struggled to balance financial goals with actually living your life, this conversation will make you feel far less alone.Brittany has recently begun building a platform called Be Loan Wise, focused on helping others navigate the emotional and financial sides of student loan debt. You can follow along at @beloanwise on Instagram!Sponsors:Bayer: Check out Bayer's trusted lineup of products, available at Walmart, CVS, Amazon, and Walgreens.Pique: Unlock 20% off and begin your journey toward sustained wellness today at Piquelife.com/REALSTUFFWatch this episode in video form on YouTube: https://www.youtube.com/playlist?list=PLjmevEcbh5h5FEX0pazPEtN86t7eb2OgX To apply to be a guest on the show, visit luciefink.com/apply and send us your story. I also want to extend a special thank you to East Love for the show's theme song, Rolling Stone. Follow the show on Instagram: https://www.instagram.com/therealstuffpod Find Lucie here: Instagram: https://www.instagram.com/luciebfink/ TikTok: https://www.tiktok.com/@luciebfink YouTube: https://www.youtube.com/luciebfinkWebsite: https://luciefink.com/ Subscribe to my free newsletter "The Lucie List" here: https://thelucielist.beehiiv.com/subscribeSubscribe to "The Creator Confidential": http://www.luciefink.com/confidentialExecutive Producer: Cloud10Produced by Dear Media.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Choosing traits for new canola varieties goes well beyond yield, with breeders balancing disease resistance, lodging tolerance, maturity, and other agronomic needs that vary by farm and region. That approach was the focus of a conversation at Canola Week in Saskatoon, where RealAgriculture spoke with Jed Christianson, Bayer’s product design canola lead, about how Bayer... Read More

本集節目由【西谷子 力度伸接骨木莓飲+鋅】贊助播出 孩子的成長日常，就是爸媽的生活日常。 來自德國 Bayer 的「力度伸 接骨木莓＋鋅」 結合接骨木莓與鋅等營養成分 提供適合日常補充的新選擇，陪伴全家每一天

On today's show, guest host Bert Zipperer speaks with dairy journalist Pete Hardin. They recap the big stories in the agricultural industry over 2025, in an extension of their coverage on their weekly feature on WORT, The Milkweed.  Dairy and cheese production is quintessentially Wisconsin, since the time that settler farmers brought their herds to regenerate the land cleared of forests by an earlier generation of settlers. Hardin calls Wisconsin's dairy industry the greatest non-extractive economic development of the state. Now, dairy is a $50-60 billion dollar industry, with celebrated small producers like Cedar Grove and large producers like BelGioioso.  But the cheese market is terrible right now, says Hardin. Since 2024, prices have declined 30-35%. On top of declining gains for producers, immigrant farmworkers are being targeted by the Trump administration, despite the foundational role they play in the nation’s agricultural sector. The agricultural sector as a whole is struggling, from the ravages of the avian flu to the Trump administration's tariffs that hit the soybean market hard. And then there are the lawsuits against Monsanto and Bayer, the producers of the carcinogenic herbicide called glyphosate or Roundup, that the Trump administration wants to overturn. In this market, Hardin says that he's worried about hungry farmers and hungry consumers. Featured image of the Old Country Cheese plant in Cashton, Wisconsin via Rawpixel.  Did you enjoy this story? Your funding makes great, local journalism like this possible. Donate hereThe post Hungry Farmers and Hungry Consumers appeared first on WORT-FM 89.9.

Shunji Tomatsu, MD, PhD, Professor and Head, Nemours Children's Health, Delaware, USA; Alessandra d'Azzo, PhD, Emerita Faculty, Genetics, St. Jude Children's Research Hospital, Tennessee, USA; Merve Emecen Sanli, MD, Associate Professor, Department of Pediatrics, University of Texas Southwestern Medical Center, Texas, USA; and Ryan Colburn, patient with Pompe disease and president of Odimm Inc, discuss new and emerging gene therapies for lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, please visit https://checkrare.com/learning/p-grids2025-session6-current-issues-in-gene-therapies-for-lysosomal-disorders/  Learning ObjectivesDescribe current and emerging gene therapy data in lysosomal disorders and its clinical relevanceDescribe role of patients in gene therapy developmentFacultyShunji Tomatsu, MD, PhD, Professor and Head, Nemours Children's HealthAlessandra d'Azzo, PhD, Emerita Faculty, Genetics, St. Jude Children's Research HospitalMerve Emecen Sanli, MD, Associate Professor, Department of Pediatrics, University of Texas Southwestern Medical CenterRyan Colburn. Odimm, Inc.DisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Shunji Tomatsu, MD, PhD Dr. Tomatsu has received the following grants: Morquio Foundations and families: Scarlett Grifith, Bennett, A Cure for Roberts, and Morquio Conference; MPS Societies: Japanese, National, and Austrian; NIH grants: 1-R01-HD102545, NIH, NICHD, Tomatsu (PI), 1R01HD104814-01A1, NIH, NICHD, Langan, T.J. (PI), Role: Site-PI, R43HD114328-01, NIH, ACOSTA, WALTER (PI), Role: site PI, 1R43AR084638-01, NIH, MOUNZIH, KHALID (PI); Foundation of NIH: FNIH RFP NUMBER: 2022-BGTC-005 Tomatsu (PI). Alessandra d'Azzo, PhDDr. D'Azzo has no relevant financial relationships to disclose.Merve Emecen Sanli, MDDr. Sanli has no relevant financial relationships to disclose.Ryan ColburnMr. Colburn has an advisory, consulting and/or project based relationship or stock holding with: Abeona Therapeutics, Amicus Therapeutics, Astellas Gene Therapies, Avidity Biosciences, Bayer, Catalyst Pharmaceuticals, Denali Therapeutics, M6P Therapeutics, Sangamo Therapeutics, Sanofi, Solid Biosciences.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Silvester unterm Kreuz, was bietet sich da also mehr an als der Blick nach vorne auf das anstehende Jahr 2026? Lara, Nils, Pippo und Kevin haben jeweils eine These für das Bayer-04-Jahr mitgebracht, die eine gewagter, die andere etwas vorsichtiger und geben sie zum Besten. Von Tabellenführung, Titel, Transfers und Verbleib ist alles dabei. Ende 2026 werden wir diese dann auflösen. Schreibt uns gerne eure Thesen über unsere Social-Media-Kanäle, dann werden wir die auch in die Analyse einbeziehen. Habt einen guten Rutsch ins neue Jahr, bleibt gesund und auf erfolgreiche Spiele und vielleicht eine gemeinsame Reise nach Berlin im Mai? Das wär doch ...Dieser Podcast wird vermarktet von der Podcastbude.www.podcastbu.de - Full-Service-Podcast-Agentur - Konzeption, Produktion, Vermarktung, Distribution und Hosting.Du möchtest deinen Podcast auch kostenlos hosten und damit Geld verdienen?Dann schaue auf www.kostenlos-hosten.de und informiere dich.Dort erhältst du alle Informationen zu unseren kostenlosen Podcast-Hosting-Angeboten. kostenlos-hosten.de ist ein Produkt der Podcastbude.

Bayer Crop Science's seed production plants play a critical role in ensuring the performance farmers expect from DEKALB® corn and Asgrow® soybeans.In this Managing for Profit, Clint Rodenberg, production lead for DEKALB brand, and Drew Yingling, plant production manager at Bayer's Stonington, Illinois, Asgrow soybean production facility, share how the process starts long before farmers ever open a bag of seed.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jaciara is a transracial/international adoptee. She was adopted from Brazil in 1985 when she was 11 months old and raised in Northern California by a Jewish single parent mother, in a small and very minimally diverse town. Jaciara has obtained her Master's degree in Social Work and her bachelor's degree in Psychology. She currently works as a medical social worker in a hospital and has been in this field for many years. Jaciara has also worked in the field of adoption/foster care at various capacities for 10 years, and recently has begun a new part-time role as a Court Appointed Family Engagement Specialist. She has been a panelist on numerous adult adoptee panels, has co-developed and presented training curriculum utilizing both her lived and professional experience on the multi-layered experiences and nuances in transracial placement/adoption. She has also created educational curriculum for adoptee youth teaching mindfulness practices, as well as sharing learned life lessons and hardships from her lived experience in effort to provide the support and knowledge she so greatly wished to have had when she was younger. Jaciara has also independently provided 1:1 mentorship primarily to teenage adoptees including extending support/guidance to their adoptive parent(s). Jaciara is a member of the Board of Directors for S.P.A.C.E. (School of Performing Arts and Cultural Education) a well-known organization in her hometown that she actively participated in as a youth; she holds the position as the Chair of the board's Cultural Education Committee. Outside of her professional work, her most cherished and beloved hobby is Samba dance; and she is a principal dancer on a award winning Samba team. For Jaciara, Samba has been her most steady connection to her Afro-Brazilian roots.Resources/References: https://youtu.be/dmfxulaeMZI?si=exMTT3VX9SZkqXuB http://www.radiocurious.org/2015/03/31/bayer-jaciara-jaciara-bayer-transracial-adoptions-and-white-privilege/ https://www.patreon.com/c/adopteelandMusic by Corey Quinn

Drs Harrington and Gibson's annual review of cardiovascular medicine: ACS guidelines, antiplatelet management, GLP-1s, and ever lower LDL-C with drugs or even gene editing are among the highlights. This podcast is intended for healthcare professionals only. To read a transcript or to comment, visit https://www.medscape.com/author/bob-harrington New ACS Guidelines 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes https://doi.org/10.1161/CIR.0000000000001309 ACS Guideline Chair and Vice-Chair Discussion https://www.medscape.com/viewarticle/acs-guidelines-2025-key-points-chair-and-vice-chair-2025a100093l Antiplatelet/Antithrombotic Strategies Prasugrel Beats Ticagrelor in High-Risk Patients With Diabetes After PCI https://www.medscape.com/viewarticle/prasugrel-beats-ticagrelor-high-risk-patients-diabetes-after-2025a1000wbt Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes (NEO-MINDSET) https://www.nejm.org/doi/full/10.1056/NEJMoa2507980 Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation (AQUATIC) https://www.nejm.org/doi/full/10.1056/NEJMoa2507532 Bayesian Machine Learning Model Guiding Iterative, Personalized Anticoagulant Dosing Decision-Making : ENGAGE AF-TIMI 48 Trial Analysis https://doi.org/10.1016/j.jacadv.2025.102504 Factor XI Inhibitors Bristol Myers, J&J Stop Blood Clotting Drug Trial After Interim Review https://www.medscape.com/s/viewarticle/bristol-myers-j-j-stop-blood-clotting-drug-trial-after-2025a1000vqu Bayer's Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention https://www.bayer.com/en/us/news-stories/oceanic-stroke OAC-Naive Subgroup From OCEANIC-AF Published https://www.medscape.com/viewarticle/novel-blood-thinner-shows-promise-atrial-fibrillation-2025a10008lz GLP-1 and Myotrophic Drugs Lilly's Next-gen Drug Shows Greater Weight Loss Than Zepbound in Late-stage Trial (TRIUMPH-4) https://www.medscape.com/s/viewarticle/lillys-next-gen-drug-tops-zepbound-weight-loss-late-stage-2025a1000ys1 Amylin Analog Eloralintide Reduces Weight in Phase 2 Trial https://www.medscape.com/viewarticle/amylin-analog-eloralintide-reduces-weight-phase-2-trial-2025a1000uqf CRISPR and Lipid Lowering Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease https://www.nejm.org/doi/full/10.1056/NEJMoa2504747 Gene Therapy Shows Lipid Improvement but Raises Flags https://www.medscape.com/viewarticle/gene-therapy-shows-lipid-improvement-raises-flags-2025a1000uzw Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 https://www.nejm.org/doi/full/10.1056/NEJMoa2511778 Evolocumab in Patients without a Previous Myocardial Infarction or Stroke (VESALIUS-CV) https://www.nejm.org/doi/pdf/10.1056/NEJMoa2514428 Prehospital GLP IIb/IIIa Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction (CELEBRATE) https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500268 You may also like: Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology https://www.medscape.com/twic Questions or feedback, please contact news@medscape.net

Hermann Haller, MD, PhD President, Professor, MDI Biological Laboratory; Professor, Department of Nephrology and Hypertension, Hannover Medical School Haller received his medical degree from the Free University of Berlin and completed his postdoctoral work at Yale University. He has published more than 700 peer-reviewed articles, holds six world-wide patents and has founded four biotech companies. He has received many honors and awards and serves on numerous advisory boards, including those of Bayer, Boehringer Ingelheim, Genzyme and Novo Nordisk. In addition to his position at the MDI Biological Laboratory, he is also a full professor of medicine and former chairman of the Division of Nephrology at the Hannover Medical School in Germany. INNOVATORS is a podcast production of Harris Search Associates.      *The views and opinions shared by the guests on INNOVATORS do not necessarily reflect the views of the interviewee's institution or organization.*

We wrap the week with more NAFB Trade Talk conversations recorded a few weeks ago between Chip Flory and several guests: Daryl Theis of Claas on forage harvesting, Deena Hardie of Merck Animal Health on parasite and BRD management, Jarod Jacobs of ForGround by Bayer with a carbon update, Brady Spangenberg of BASF on crop protection, and Lynn Justesen of UPL.See omnystudio.com/listener for privacy information.

No último A HORA DO CONSOLO de 2025:  Daniel Bayer e João Carvalho resolvem problemas cabeludos de ouvintes traídos, ateus e namoradores de casadas.FINANCIE ESTE VACILO:apoia.se/decrepitosAssine o plano BOGA VIVA e participe do nosso GRUPO SECRETO NO TELEGRAM!MANDA PIX:livepix.gg/decrepitosPARTICIPE PELO E-MAIL:ouvinte@decrepitos.comANUNCIE COM A GENTE:comercial@decrepitos.com© Copyright 2025 - Decrépitos Podcast

On this episode of The Mark White Show, Dr. Diana Bitner, board certified OB GYN and Certified Menopause Society Practitioner, joins veteran news anchor and patient advocate Wendee Lee Curtis for an open conversation about moderate to severe hot flashes due to menopause. They discuss what these symptoms can feel like, why many women are unprepared for their impact, and the importance of talking with a healthcare professional. The conversation also includes information about Lynkuet® (elinzanetant), a newly FDA approved, hormone free treatment option for moderate to severe hot flashes due to menopause. This episode focuses on awareness, understanding, and informed conversations between women and their doctors. These guests appear on behalf of Bayer and have been compensated for their time.

Today's guest is Kun He, Lead Scientific Advisor at Bayer Crop Science. He joins Emerj Editorial Director Matthew DeMello to discuss how AI is transforming human talent and workforce development in agricultural manufacturing, balancing data-driven efficiency with the irreplaceable role of human gut instinct. Kun also explores practical takeaways, such as integrating genotyping and phenotyping data to accelerate crop-breeding workflows, empowering breeders to drive "step change" innovations, and treating AI as a co-pilot to check biases while prioritizing customer needs for blockbuster R&D outcomes. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast!

Today, we'll be tackling the future of prostate cancer care. We'll be reflecting on what prostate cancer care means in practice, how the way we think about the disease is shifting, and must continue to shift in the years ahead. Scientific advances have transformed treatment in recent years, yet the lived reality of prostate cancer still extends far beyond the clinic. The disease reshapes daily life, and may leave men and their families grappling with difficult choices about how best to manage it.  Dr. Güneş Taylor is joined by three key voices at the centre of this story, following the prostate cancer journey from diagnosis through to long-term management, and asking how patients and clinicians can work together to re-think what patient-centred care could mean in the years to come. This episode is brought to you in collaboration with Bayer, part of their Prostate Cancer Perspectives series.  PP-UN-ONC-GB-0168. November 2025 References Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263 (Prostate cancer is the second most common cancer in men and the fifth leading cause of cancer death worldwide) James D, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403(10437):1683–1722 (Each year, around 1.5 million men are diagnosed and nearly 400,000 lose their lives to the disease.1 And the numbers are rising. Diagnoses are projected to double from 1.4 million annually in 2020 to 2.9 million by 2040) Siegel RL, et al. Cancer statistics, 2022. Ca Cancer J Clin. 2022;72:7–33 (In the U.S., the proportion of men diagnosed with advanced-stage prostate cancer has doubled in recent years, due to increasing incidence of advanced-stage disease and changing guidelines regarding the prostate specific antigen screening test, implemented in the U.S. in 2012) Dodkins J, et al. Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population based evaluation. BMJ Oncology. 2025;4:e000643 (In England, nearly one in five men only receive a diagnosis once their cancer has spread) Calvo-Schimmel A, et al. Supportive care interventions and quality of life in advanced disease prostate cancer survivors: An integrative review of the literature. Can Oncol Nurs J. 2021;31(4):412-429 (Advanced prostate cancer is often associated with long-term challenges leading to greater levels of unmet needs in supportive care) Learn more about your ad choices. Visit podcastchoices.com/adchoices